MSF Access - CEPI Original Policy

# CEPI Policy Documentation

1. Equitable access policy
2. Shared risks/shared benefits policy
3. Management of intellectual property

# Introduction

This document supports awardees and potential awardees of CEPI funding in understanding CEPI’s mission and role, as well the expectations on awardees and CEPI in working together to develop new vaccines to prevent future epidemics. This document is to guide potential awardees in responding to Calls for Proposals and the establishment of contracts between CEPI and awardees.

# CEPI’s role

CEPI’s mission is to stimulate, finance and co-ordinate vaccine development against emerging infectious diseases with epidemic potential by partnering with relevant stakeholders from the public and private sectors (academia, governments, philanthropies, NGOs and industry). Developing vaccines before the epidemics arise will allow the global health community to prevent outbreaks from becoming international public health emergencies, contain loss of life, limit social and economic disruption, and protect against future epidemics.

CEPI’s contractual agreements with awardees will be guided by our three core operating principles:

Equitable access • Cost coverage c Shared benefits

This document outlines CEPI’s three policies of equitable access policy, shared risks/shared benefits policy and management of intellectual property (IP).

Equitable access is CEPI’s most important principle; the policies on shared risks/ shared benefits and management of IP support CEPI’s aim of achieving equitable access to CEPIsupported vaccines.

CEPI expects to make awards to non-profit organisations, government research institutions and academic institutions, as well as for-profit organisations including small and medium sized biotechnology companies, developing country vaccine manufacturers and multinational organisations.

This policy should be interpreted in the context of markets for vaccines for diseases with epidemic potential being very unusual in that successful vaccines may never be used; if they are used, the demand for such vaccines may be erratic, unpredictable and unlikely to be at a sufficient level to allow manufacturers to benefit from large economies of scale. CEPI recognizes that awardees willing to develop vaccines for diseases with epidemic potential are doing so in response to global health concerns. Since CEPI expects to partner with many different types of awardees (as outlined above), the Board may on a case-by-case basis allow justified exceptions from this policy to fit specific types of awardees – recognizing that some awardees will need to partner with others to achieve CEPI’s aims. In some cases CEPI may invest in organisations running programmes that are dedicated to CEPI’s mission (dedicated programmes, as defined below).

To fulfil CEPI’s vision, CEPI will take an end-to-end approach to vaccine development,

# meaning:

during product development CEPI will fund and co-ordinate development up to and incl

... (truncated, 28 KB total)